Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Holding NKTR?
Track your performance easily

Nektar Therapeutics (NKTR) Ownership - Who Owns Nektar Therapeutics?

1,208 Followers

Nektar Therapeutics (NKTR) Ownership Overview

12.28%24.06%45.30%18.36%
12.28% Insiders
45.30% Other Institutional Investors
18.36% Public Companies and
Individual Investors
The ownership structure of Nektar Therapeutics (NKTR) stock is a mix of institutional, retail and individual investors. Approximately 69.36% of the company’s stock is owned by Institutional Investors, 12.28% is owned by Insiders and 18.36% is owned by Public Companies and Individual Investors.
The ownership structure of Nektar Therapeutics (NKTR) stock is a mix of institutional, retail and individual investors. Approximately 69.36% of the company’s stock is owned by Institutional Investors, 12.28% is owned by Insiders and 18.36% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 20, 2024
Jonathan Zalevsky
Chief R&d Officer
xxxxxxxxxxxxx
$8788
Aug 20, 2024
Howard Robin
President & Ceo,director
xxxxxxxxxxxxx
$19048
May 20, 2024
Jonathan Zalevsky
Chief R&d Officer
xxxxxxxxxxxxx
$12871
May 20, 2024
Howard Robin
President & Ceo,director
xxxxxxxxxxxxx
$29138

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$33907
Jun 30, 2024
xxxxxxxxxxxxx
$772402
Jun 30, 2024
xxxxxxxxxxxxx
$7465361

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
18,700,000Institution10.16%23,562,000
12,491,422Institution6.79%15,739,192
10,049,038Institution5.46%12,661,788
7,529,096Institution4.09%9,486,661
7,136,462Institution3.88%8,991,942
6,305,736Institution3.43%7,945,227
6,020,453Institution3.27%7,585,771
2,280,412Institution1.24%2,873,319
1,949,449Institution1.06%2,456,306
1,709,346Institution0.93%2,153,776

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
12,491,422Institution6.79%15,739,192
7,529,096Institution4.09%9,486,661
6,305,736Institution3.43%7,945,227
2,280,412Institution1.24%2,873,319
1,949,449Institution1.06%2,456,306
1,709,346Institution0.93%2,153,776
1,641,025Institution0.89%2,067,692
1,181,405Institution0.64%1,488,570
1,055,632Institution0.57%1,330,096
795,362Institution0.43%1,002,156

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
5,724,732Institution3.11%7,671,141
4,965,959Institution2.70%6,257,108
2,918,369Institution1.59%3,910,614
1,754,656Institution0.95%2,210,867
847,714Institution0.46%1,102,028
701,033Institution0.38%939,384
569,466Institution0.31%763,084
534,427Institution0.29%673,378
415,847Institution0.23%523,967
158,445Institution0.09%205,979

FAQ

Who Owns Nektar Therapeutics (NKTR)?
According to the latest TipRanks data, approximately 45.30% of the company's stock is held by institutional investors, 12.28% is held by insiders, and 18.36% is held by retail investors.
    What percentage of Nektar Therapeutics (NKTR) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 45.30% of Nektar Therapeutics (NKTR) stock is held by institutional investors.
      What percentage of Nektar Therapeutics (NKTR) stock is held by retail investors?
      According to the latest TipRanks data, approximately 18.36% of Nektar Therapeutics (NKTR) stock is held by retail investors.
        Who owns the most shares of Nektar Therapeutics (NKTR)?
        Peter Kolchinsky owns the most shares of Nektar Therapeutics (NKTR).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis